208 related articles for article (PubMed ID: 32300639)
1. Tumor Control by Cytomegalovirus: A Door Open for Oncolytic Virotherapy?
Herbein G; Nehme Z
Mol Ther Oncolytics; 2020 Jun; 17():1-8. PubMed ID: 32300639
[TBL] [Abstract][Full Text] [Related]
2. Oncolytic Virotherapy by HSV.
Watanabe D; Goshima F
Adv Exp Med Biol; 2018; 1045():63-84. PubMed ID: 29896663
[TBL] [Abstract][Full Text] [Related]
3. Enhanced antiglioma activity of chimeric HCMV/HSV-1 oncolytic viruses.
Shah AC; Parker JN; Gillespie GY; Lakeman FD; Meleth S; Markert JM; Cassady KA
Gene Ther; 2007 Jul; 14(13):1045-54. PubMed ID: 17429445
[TBL] [Abstract][Full Text] [Related]
4. Oncolytic Herpes Simplex Virus Vectors Fully Retargeted to Tumor- Associated Antigens.
Uchida H; Hamada H; Nakano K; Kwon H; Tahara H; Cohen JB; Glorioso JC
Curr Cancer Drug Targets; 2018; 18(2):162-170. PubMed ID: 28176649
[TBL] [Abstract][Full Text] [Related]
5. Engineering Newcastle Disease Virus as an Oncolytic Vector for Intratumoral Delivery of Immune Checkpoint Inhibitors and Immunocytokines.
Vijayakumar G; McCroskery S; Palese P
J Virol; 2020 Jan; 94(3):. PubMed ID: 31694938
[TBL] [Abstract][Full Text] [Related]
6. Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy.
Rojas JJ; Sampath P; Hou W; Thorne SH
Clin Cancer Res; 2015 Dec; 21(24):5543-51. PubMed ID: 26187615
[TBL] [Abstract][Full Text] [Related]
7. Tumor Microenvironment Remodeling by Intratumoral Oncolytic Vaccinia Virus Enhances the Efficacy of Immune-Checkpoint Blockade.
Chon HJ; Lee WS; Yang H; Kong SJ; Lee NK; Moon ES; Choi J; Han EC; Kim JH; Ahn JB; Kim JH; Kim C
Clin Cancer Res; 2019 Mar; 25(5):1612-1623. PubMed ID: 30538109
[TBL] [Abstract][Full Text] [Related]
8. Development of a second-generation oncolytic Herpes simplex virus expressing TNFalpha for cancer therapy.
Han ZQ; Assenberg M; Liu BL; Wang YB; Simpson G; Thomas S; Coffin RS
J Gene Med; 2007 Feb; 9(2):99-106. PubMed ID: 17256802
[TBL] [Abstract][Full Text] [Related]
9. The Human Cytomegalovirus, from Oncomodulation to Oncogenesis.
Herbein G
Viruses; 2018 Aug; 10(8):. PubMed ID: 30081496
[TBL] [Abstract][Full Text] [Related]
10. Human Cytomegalovirus UL111A and US27 Gene Products Enhance the CXCL12/CXCR4 Signaling Axis via Distinct Mechanisms.
Tu CC; Arnolds KL; O'Connor CM; Spencer JV
J Virol; 2018 Mar; 92(5):. PubMed ID: 29237840
[TBL] [Abstract][Full Text] [Related]
11. Eliminating established tumor in nu/nu nude mice by a tumor necrosis factor-alpha-related apoptosis-inducing ligand-armed oncolytic adenovirus.
Dong F; Wang L; Davis JJ; Hu W; Zhang L; Guo W; Teraishi F; Ji L; Fang B
Clin Cancer Res; 2006 Sep; 12(17):5224-30. PubMed ID: 16951242
[TBL] [Abstract][Full Text] [Related]
12. The retinoblastoma tumor suppressor promotes efficient human cytomegalovirus lytic replication.
VanDeusen HR; Kalejta RF
J Virol; 2015 May; 89(9):5012-21. PubMed ID: 25694602
[TBL] [Abstract][Full Text] [Related]
13. Herpes simplex virus delivery to orthotopic rectal carcinoma results in an efficient and selective antitumor effect.
Kolodkin-Gal D; Edden Y; Hartshtark Z; Ilan L; Khalaileh A; Pikarsky AJ; Pikarsky E; Rabkin SD; Panet A; Zamir G
Gene Ther; 2009 Jul; 16(7):905-15. PubMed ID: 19440231
[TBL] [Abstract][Full Text] [Related]
14. Oncolytic virotherapy enhances the efficacy of a cancer vaccine by modulating the tumor microenvironment.
Koske I; Rössler A; Pipperger L; Petersson M; Barnstorf I; Kimpel J; Tripp CH; Stoitzner P; Bánki Z; von Laer D
Int J Cancer; 2019 Oct; 145(7):1958-1969. PubMed ID: 30972741
[TBL] [Abstract][Full Text] [Related]
15. An armed oncolytic herpes simplex virus expressing thrombospondin-1 has an enhanced in vivo antitumor effect against human gastric cancer.
Tsuji T; Nakamori M; Iwahashi M; Nakamura M; Ojima T; Iida T; Katsuda M; Hayata K; Ino Y; Todo T; Yamaue H
Int J Cancer; 2013 Jan; 132(2):485-94. PubMed ID: 22729516
[TBL] [Abstract][Full Text] [Related]
16. Human Cytomegalovirus UL135 and UL136 Genes Are Required for Postentry Tropism in Endothelial Cells.
Bughio F; Umashankar M; Wilson J; Goodrum F
J Virol; 2015 Jul; 89(13):6536-50. PubMed ID: 25878111
[TBL] [Abstract][Full Text] [Related]
17. New inhibitors of cytomegalovirus replication: in vitro evaluation, mechanism of action, and in vivo activity.
Neyts J; De Clercq E
Verh K Acad Geneeskd Belg; 1994; 56(6):561-92. PubMed ID: 7892749
[TBL] [Abstract][Full Text] [Related]
18. Oncolytic viruses and checkpoint inhibitors: combination therapy in clinical trials.
LaRocca CJ; Warner SG
Clin Transl Med; 2018 Nov; 7(1):35. PubMed ID: 30426287
[TBL] [Abstract][Full Text] [Related]
19. Dendritic cells in cytomegalovirus infection: viral evasion and host countermeasures.
Rölle A; Olweus J
APMIS; 2009 May; 117(5-6):413-26. PubMed ID: 19400865
[TBL] [Abstract][Full Text] [Related]
20. Oncolytic virus therapy using genetically engineered herpes simplex viruses.
Todo T
Front Biosci; 2008 Jan; 13():2060-4. PubMed ID: 17981691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]